SLC5A2 and diabetes mellitus: The latter is reinforced by current data showing that patients with HFDM have not responded favourably to various cardiac‐orientated pharmacological treatments that have otherwise proven effective in patients with HF or DM,38, 39, 40, 41, 42, 43 although sodium glucose co‐transporter 2 (SGLT2) inhibitors may be one recent exception in which there is no interaction with the presence or absence of DM.44, 45